

**BEST AVAILABLE COPY**

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property Organization  
International Bureau**



**(43) International Publication Date  
21 June 2001 (21.06.2001)**

**PCT**

**(10) International Publication Number  
WO 01/44181 A1**

**(51) International Patent Classification<sup>7</sup>:** C07D 207/34    **(74) Agents:** O'BRIEN, John, A. et al.; John A O'Brien & Associates, Duncairn House, Third Floor, 14 Carysfort Avenue, Blackrock, County Dublin (IE).

**(21) International Application Number:** PCT/IE00/00151

**(22) International Filing Date:** 18 December 2000 (18.12.2000)

**(25) Filing Language:** English

**(26) Publication Language:** English

**(30) Priority Data:**  
PCT/IE99/00133    17 December 1999 (17.12.1999) IE

**(71) Applicant (for all designated States except US):** WARNER LAMBERT RESEARCH AND DEVELOPMENT IRELAND LIMITED [IE/IE]; Pottery Road, Dun Laoghaire, County Dublin (IE).

**(72) Inventors; and**

**(75) Inventors/Applicants (for US only):** O'CONNELL, John [IE/IE]; 13 Manor Avenue, Thornbury Heights, Rochestown, Cork (IE). TULLY, William [IE/IE]; Ballyedmond, Midleton, County Cork (IE). MADIGAN, Evelyn [IE/IE]; 1 Glenwood Dale, Carrigaline, County Cork (IE).

**(81) Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

**(84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/44181 A1

---

**(54) Title:** A PROCESS FOR PRODUCING CRYSTALLINE ATORVASTATIN CALCIUM

**(57) Abstract:** A factory scale process for producing crystalline atorvastatin calcium includes the step of drying the isolated product in a vacuum pan dryer. The vacuum pan dryer has an agitator which is continuously rotated at a speed of approximately 1 rpm. High quality material is routinely and consistently produced with reduced cycle time.

- 1 -

A PROCESS FOR PRODUCING CRYSTALLINE ATORVASTATIN CALCIUM

Introduction

5 The invention relates to an improved process for producing crystalline atorvastatin calcium which is known by the chemical name [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt.

10 Atorvastatin is useful as a selective and competitive inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols such as cholesterol. The conversion of HMG-CoA to mevalonate is an early and rate-limiting step in cholesterol biosynthesis.

15 Atorvastatin as well as some of its metabolites are pharmacologically active in humans and are thus useful as a hypolipidemic and hypocholesterolemic agent. The liver is the primary site of action and the principal site of cholesterol synthesis. Clinical and pathological studies show that elevated plasma levels of total cholesterol and associated triglycerides promote human atherosclerosis and are risk factors for developing cardiovascular disease.

20 United States Patent Number 4,681,893, which is herein incorporated by reference, discloses certain trans-6-[2-(3- or 4-carboxamido-substituted-pyrrol-1-yl) alkyl]-4-hydroxy-pyran-2-ones including trans ( $\pm$ )-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[(2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide.

25 United States Patent Number 5,273,995, which is herein incorporated by reference, discloses the enantiomer having the R form of the ring-opened acid of trans-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[(2-tetrahydro-4-

- 2 -

hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, i.e., [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ ,  $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid.

5 The above described atorvastatin compounds have been prepared by a superior convergent route disclosed in the following United States Patent Numbers 5,003,080; 5,097,045; 5,103,024; 5,124,482 and 5,149,837 which are herein incorporated by reference and Baumann K.L., Butler D.E., Deering C.F., et al, *Tetrahedron Letters* 1992;33:2283-2284.

10 One of the critical intermediates disclosed in United States Patent Number 5,097,045 has also been produced using novel chemistry, as disclosed in United States Patent Number 5,155,251, which is herein incorporated by reference and Brower P.L., Butler D.E., Deering C.F., et al, *Tetrahedron Letters* 1992;33:2279-15 2282.

15 United States Patent Numbers 5,216,174; 5,245,047; 5,248,793; 5,280,126; 5,397,792; 5,342,952; 5,298,627; 5,446,054; 5,470,981; 5,489,690; 5,489,691; 5,109,488; 5,969,156; US6,087,511; US5,998,663 and WO99/32434 which are 20 herein incorporated by reference, disclose various processes and key intermediates for preparing atorvastatin.

It has been found that when the process for preparing atorvastatin calcium was scaled up to a commercial factory scale drying was slow and difficult to optimise.

25 It was also found that wet crystalline atorvastatin calcium was susceptible to possible break up with physical attrition and furthermore had a propensity to form rock hard clods on mixing.

- 3 -

The object of the present invention is therefore to provide a process for producing crystalline atorvastatin calcium on a factory scale which routinely and consistently produces high quality material with reduced cycle time.

5 Statements of Invention

According to the invention there is provided a process for producing crystalline atorvastatin trihydrate hemi calcium salt comprising the steps of:-

10 reacting a mixture of atorvastatin lactone, methanol and methyl *tert*-butyl ether with sodium hydroxide to form the ring-opened sodium salt;

15 forming a product rich aqueous layer and an organic layer comprising methyl *tert*-butyl ether containing impurities;

20 removing the organic layer comprising methyl *tert*-butyl ether containing impurities;

25 extracting the product rich aqueous layer with methyl *tert*-butyl ether;

30 adding an extra charge of methyl *tert*-butyl ether to a vessel containing the product rich aqueous layer in an amount of at least 1% w/v of the contents of the vessel;

sealing the reaction vessel;

heating the contents of the sealed reaction vessel to 47 to 57°C in the presence of the extra charge of methyl *tert*-butyl ether which saturates the crystallisation matrix on heating;

- 4 -

adding calcium acetate hemihydrate to the sealed reaction vessel to form atorvastatin trihydrate hemi calcium salt; and

5 drying the isolated product in a vacuum pan dryer having an agitator which is continuously rotated at a speed of from 0.5 to 2rpm.

10 It has been surprisingly found that this continuous agitation at a very low speed provides optimum drying conditions with very significant increased throughput while avoiding clod formation and particle attrition. As more solvents are evaporated from the cake in the dryer the crystals are increasingly susceptible to attrition. The process ensures that no break-up occurs with physical attrition. Clod formation on mixing is also avoided.

15 In a particularly preferred embodiment of the invention the agitator is substantially continuously rotated at a speed of approximately 1rpm. This provides reduced drying time while ensuring uniform drying of the crystals and avoidance of clod formation and particle attrition. We have found that this uniform drying ensures that all water is evenly removed from the cake in the dryer.

20 In a preferred embodiment the vacuum in the pan dryer is maintained at from -0.80 to -0.99 bar.

25 Preferably the isolated product is dried over a period of from 1 to 4 days, ideally over a period of from 1 to 2 days.


#### Detailed description

30 Atorvastatin lactone is saponified in a water/methyl alcohol/methyl *tert*-butyl ether (2-methoxy-2-methyl-propane; *tert*-butyl methyl ether) mixture with sodium hydroxide. The aqueous layer containing the sodium salt of atorvastatin is washed

- 5 -

with methyl *tert*-butyl ether to remove small quantities of process impurities. A small aliquot of methyl *tert*-butyl ether is added to the crystallisation matrix. Sodium-to-calcium salt metathesis with concurrent crystallisation is accomplished by the slow addition of an aqueous calcium acetate solution to the sodium salt solution. To ensure crystallisation simultaneous with addition, the reaction mixture is seeded with crystalline atorvastatin shortly after the start of the calcium acetate addition. The product is isolated by filtration and, after washing with water/methyl alcohol and water is centrifuged and vacuum dried before milling to give crystalline atorvastatin as the trihydrate. The reaction scheme is shown below.

5  
10



Scheme 1

15  
We have surprisingly found that the drying of atorvastatin calcium has a sensitive window of moisture content of approximately 6% w/v where the drying has to proceed slowly in order to prevent the particles from breaking down. As more solvents are evaporated from the cake in the dryer, especially around 6% water, the particles are increasingly susceptible to attrition.

20  
We have found that continuous agitation at approximately 1rpm significantly reduces the drying time compared to an intermittent agitation technique, thereby increasing drying capacity while ensuring that the final dried product is within a

- 6 -

consistent range for particle size and bulk density. This is in complete contrast to continuous medium speed agitation which results in clod formation and the risk of physical attrition and intermittent agitation which substantially increases the required drying time. Continuous agitation at 0.5 to 2 rpm is outside the normal design operating range of agitated pan dryers.

Example 1

250kg atorvastatin lactone prepared as described in US 5,273,995 the entire 10 contents of which are incorporated by reference, 1028kg methyl *tert*- butyl ether and 496kg of methanol are charged to a 6000 litre glass lined reaction vessel. The reaction mixture is agitated and heated to about 30°C to dissolve the lactone. When the lactone is dissolved, approximately 3200 litres of caustic solution is 15 added (19kg of sodium hydroxide 97.5% dissolved in 3165 litres of deionised water). The contents of the vessel are heated to 47 to 57°C and agitated for at least 45 minutes.

20 After cooling to 25 to 35°C under an inert atmosphere the contents are allowed to settle and the organic layer is discarded. 765kg methyl *tert*-butyl ether is charged to the aqueous layer, the contents mixed and allowed to settle. The organic layer is discarded.

25 63kg of extra methyl *tert*-butyl ether is charged to the product rich aqueous layer in the reaction vessel which is then sealed. The contents of the sealed reaction vessel are heated to 47 to 57°C maintaining a pressurised system.

30 A solution of calcium acetate (40kg calcium acetate hemihydrate in 1365 litres deionised water) is transferred to the pressurised vessel. Shortly after commencement of the calcium acetate addition the transfer is stopped and atorvastatin trihydrate hemi calcium salt seed, prepared as described in US5,969,156 which is herein incorporated by reference, is introduced.

- 7 -

A seed slurry is prepared by charging 37 litres deionised water and 13kg methanol to a stainless steel make-up/delivery vessel. The solvent mixture is agitated by rocking the vessel back and forth on its cradle. 3.6kg atorvastatin calcium seed crystals are then charged to the solvent mixture. The contents of the delivery vessel are mixed by rocking until a seed slurry is formed. Sufficient pressure is applied to the make-up/delivery vessel so that its pressure is higher than that of the reaction vessel. The make-up/delivery vessel is attached to the reaction vessel via a flexible hose and the seed slurry is charged rapidly over 2 to 3 minutes, under pressure, into the reaction vessel.

After the addition of the seed slurry the calcium acetate addition is immediately resumed to complete the calcium transfer.

The product cake is washed first with a methanol/water solution followed by a water wash.

Example 2: Drying of atorvastatin calcium

The wet product prepared in Example 1 is loaded into a stainless steel continuous agitation pan dryer such as a Guedu Pan Dryer. A full vacuum of from -0.80 to -0.99 bar is applied, the jacket of the dryer adjusted to 60 to 70°C and the product dried with slow continuous agitation at approximately 1rpm for at least 24 hours, preferably for from 1 to 4 days, ideally 1 to 2 days.

The dry product is then loaded into clean poly-lined drums.

The invention is not limited to the embodiments hereinbefore described which may be varied in detail.

Claims

1. A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt comprising the steps of:-

5

reacting a mixture of atorvastatin lactone, methanol and methyl *tert*-butyl ether with sodium hydroxide to form the ring-opened sodium salt;

10

forming a product rich aqueous layer and an organic layer comprising methyl *tert*-butyl ether containing impurities;

removing the organic layer comprising methyl *tert*-butyl ether containing impurities;

15

extracting the product rich aqueous layer with methyl *tert*-butyl ether;

20

adding an extra charge of methyl *tert*-butyl ether to a vessel containing the product rich aqueous layer in an amount of at least 1% w/v of the contents of the vessel;

sealing the reaction vessel;

25

heating the contents of the sealed reaction vessel to 47 to 57°C in the presence of the extra charge of methyl *tert*-butyl ether which saturates the crystallisation matrix on heating;

30

adding calcium acetate hemihydrate to the sealed reaction vessel to form atorvastatin trihydrate hemi calcium salt; and

- 9 -

drying the isolated product in a vacuum pan dryer having an agitator which is continuously rotated at a speed of from 0.5 to 2rpm.

2. A process as claimed in claim 1 wherein the agitator is substantially continuously rotated at a speed of approximately 1rpm.

5 3. A process as claimed in claim 1 or 2 wherein the vacuum in the pan dryer is maintained at from -0.80 to -0.99 bar.

10 4. A process as claimed in any preceding claim wherein the isolated product is dried over a period of from 1 to 4 days.

5. A process as claimed in any preceding claim wherein the isolated product is dried over a period of from 1 to 2 days.

15

# INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/IE 00/00151

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07D207/34

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 102 648 A (CARPENTER LARRY D ET AL) 7 April 1992 (1992-04-07) column 4, line 41 - line 47 ---	1-5
Y	GRAUL A ET AL: "ATORVASTATIN CALCIUM" DRUGS OF THE FUTURE, ES, BARCELONA, vol. 22, no. 9, 1997, pages 956-968-968, XP000904817 ISSN: 0377-8282 page 957 ---	1-5
Y	WO 97 03958 A (WARNER LAMBERT CO ;MCKENZIE ANN T (US)) 6 February 1997 (1997-02-06) examples 1,2 ---	1-5 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

28 March 2001

16/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Gettins, M

# INTERNATIONAL SEARCH REPORT

Internati	Application No
PCT/IE 00/00151	

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 03959 A (WARNER LAMBERT CO ;BRIGGS CHRISTOPHER A (US); JENNINGS REX ALLEN ()) 6 February 1997 (1997-02-06) page 20 -page 21 ----	1-5
Y	US 5 216 174 A (NANNINGA THOMAS N ET AL) 1 June 1993 (1993-06-01) cited in the application claim 7 ----	1-5
Y	US 3 852 480 A (WILLIAMS W) 3 December 1974 (1974-12-03) column 3, line 22 - line 23 ----	1-5
Y	US 3 897 307 A (PORUBCAN RANDOLPH S ET AL) 29 July 1975 (1975-07-29) column 3, line 35 - line 36 ----	1-5
Y	US 5 273 995 A (ROTH BRUCE D) 28 December 1993 (1993-12-28) cited in the application Scheme 1 column 4 -column 5 ----	1-5

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat. Application No

PCT/IE 00/00151

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 5102648	A 07-04-1992	US 5028408 A			02-07-1991
		AU 7452191 A			18-09-1991
		BR 9106103 A			24-02-1993
		CA 2076856 A			03-09-1991
		EP 0517782 A			16-12-1992
		ES 2093093 T			16-12-1996
		JP 5504931 T			29-07-1993
		WO 9113025 A			05-09-1991
-----	-----	-----	-----	-----	-----
WO 9703958	A 06-02-1997	AU 725368 B			12-10-2000
		AU 6484196 A			18-02-1997
		BG 102186 A			30-10-1998
		BR 9610567 A			06-07-1999
		CA 2220458 A			06-02-1997
		CN 1190957 A			19-08-1998
		CZ 9800123 A			17-06-1998
		EP 0848704 A			24-06-1998
		HR 960313 A			30-04-1998
		HU 9901687 A			28-10-1999
		IL 122162 A			14-07-1999
		JP 11509229 T			17-08-1999
		NO 980208 A			16-01-1998
		PL 324532 A			08-06-1998
		SK 5998 A			06-05-1998
		US 6121461 A			19-09-2000
-----	-----	-----	-----	-----	-----
WO 9703959	A 06-02-1997	AU 725424 B			12-10-2000
		AU 6484296 A			18-02-1997
		BG 102187 A			30-10-1998
		BR 9609872 A			23-03-1999
		CA 2220018 A			06-02-1997
		CN 1190955 A			19-08-1998
		CZ 9800121 A			14-10-1998
		EP 0848705 A			24-06-1998
		HR 960339 A			30-04-1998
		HU 9900678 A			28-07-1999
		IL 122118 A			14-07-1999
		JP 11509230 T			17-08-1999
		NO 980207 A			16-01-1998
		PL 324496 A			25-05-1998
		SK 6298 A			07-10-1998
		US 5969156 A			19-10-1999
-----	-----	-----	-----	-----	-----
US 5216174	A 01-06-1993	US 5003080 A			26-03-1991
		US 5097045 A			17-03-1992
		US 5124482 A			23-06-1992
		US 5149837 A			22-09-1992
		US 5245047 A			14-09-1993
		US 5280126 A			18-01-1994
		AT 109777 T			15-08-1994
		AU 634689 B			25-02-1993
		AU 1601792 A			09-07-1992
		AU 635171 B			11-03-1993
		AU 1601892 A			09-07-1992
		AU 3349689 A			06-09-1989
		AU 621874 B			26-03-1992
		CA 1330441 A			28-06-1994
		DE 68917336 D			15-09-1994

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IE 00/00151

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5216174	A	DE	68917336 T	01-12-1994
		DK	197090 A	04-10-1990
		EP	0330172 A	30-08-1989
		EP	0448552 A	02-10-1991
		ES	2058356 T	01-11-1994
		FI	94958 B	15-08-1995
		FI	941550 A, B,	05-04-1994
		HK	1000732 A	24-04-1998
		IE	63994 B	28-06-1995
		JP	3009139 B	14-02-2000
		JP	10195071 A	28-07-1998
		JP	2843627 B	06-01-1999
		JP	3502798 T	27-06-1991
		KR	9711578 B	12-07-1997
		KR	123813 B	27-11-1997
		KR	9711462 B	11-07-1997
		KR	137884 B	01-05-1998
		KR	9711579 B	12-07-1997
		NO	177566 B	03-07-1995
		NO	941725 A, B,	27-09-1990
		NO	943057 A, B,	27-09-1990
		NO	951075 A, B,	27-09-1990
		NO	963245 A	27-09-1990
		NZ	228050 A	29-01-1992
		NZ	238843 A	29-01-1992
		NZ	238844 A	29-01-1992
		NZ	238845 A	29-01-1992
		PT	89774 A, B	04-10-1989
		WO	8907598 A	24-08-1989
		ZA	8900989 A	31-10-1990
US 3852480	A	03-12-1974	NONE	
US 3897307	A	29-07-1975	AU	473243 B
			AU	8014475 A
			BE	828181 A
			CA	1041929 A
			CH	596302 A
			DE	2520128 A
			DK	199975 A, B,
			FR	2299404 A
			GB	1469218 A
			IT	1049418 B
			NL	7505227 A
			NO	751586 A, B,
			SE	422079 B
			SE	7507580 A
US 5273995	A	28-12-1993	MX	9203143 A
			AU	628198 B
			AU	5972490 A
			CA	2021546 A, C
			EP	1061073 A
			EP	0409281 A
			ES	2153332 T
			FI	94339 B
			IE	902659 A
			JP	3058967 A

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internati Application No

PCT/IE 00/00151

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5273995	A	KR	167101 B	15-01-1999
		NO	174709 B	14-03-1994
		NO	176096 B	24-10-1994
		NZ	234576 A	23-12-1992
		PT	94778 A, B	20-03-1991
		SG	46495 A	20-02-1998
		ZA	9005742 A	25-03-1992

**THIS PAGE BLANK (USPTO)**